<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty-one patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or overt <z:hpo ids='HP_0001909'>leukemia</z:hpo> resulting from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were treated with recombinant human granulocyte colony-stimulating factor (rhG-CSF) and <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (Ara-C) </plain></SENT>
<SENT sid="1" pm="."><plain>Ara-C was administered in a dose of 20 mg/m2 every 12 h for 5 days and after 2 days 125 micrograms of rhG-CSF was administered for 10 days </plain></SENT>
<SENT sid="2" pm="."><plain>After recovery of the leukocyte count the therapy was repeated, doubling the dose of Ara-C serially when possible </plain></SENT>
<SENT sid="3" pm="."><plain>Of 13 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, four achieved complete remission (CR), two good response (GR), two minor response (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>), and five no response (NR) </plain></SENT>
<SENT sid="4" pm="."><plain>Of eight patients with overt <z:hpo ids='HP_0001909'>leukemia</z:hpo> from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, only one with hyperplastic bone marrow achieved a partial response (PR) and the remaining seven achieved NR </plain></SENT>
<SENT sid="5" pm="."><plain>The efficacy of the combination of rhG-CSF and Ara-C in the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and its leukemic phase is discussed, including at which time rhG-CSF should be administered: before, after or concomitantly with Ara-C </plain></SENT>
<SENT sid="6" pm="."><plain>Multicenter randomized studies are needed in the evaluation of this combination therapy </plain></SENT>
</text></document>